你即將離開本站

並前往https://www.astrazeneca-us.com/media/press-releases/2022/lynparza-olaparib-plus-abiraterone-reduced-risk-of-disease-progression-by-34-vs-standard-of-care-in-1st-line-metastatic-castration-resistant-prostate-cancer-02142022.html

LYNPARZA® (olaparib) plus abiraterone ... - AstraZeneca US

PROpel Phase III trial results show clinically meaningful benefit in ... model including terms for treatment group, the subgroup factor, ...

確定！ 回上一頁

查詢 「IARC group 3」的人也找了：

  1. IARC Group 3
    2.
  2. iarc分類
    3.
  3. iarc分類2021
    4.
  4. iarc分類2020
    5.
  5. IARC Group 1
    6.
  6. IARC 2A
    7.
  7. IARC 2B
    8.
  8. Carcinogen
    9.